Latest action: Referred to the House Committee on Foreign Affairs.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Establishes U.S. leadership in biotechnology diplomacy and international cooperation.
The problem
The U.S. faces competition from other countries in biotechnology research and development. International collaboration on biotech is fragmented and lacks coordinated strategy.
The proposal
Creates diplomatic initiatives and frameworks for U.S. biotechnology leadership globally. Coordinates with allies on research standards and partnership development.
The impact
U.S. scientists, biotech companies, foreign governments, and research institutions gain structured pathways for collaboration and competition in biotechnology fields.
Positions America as a leader in biotechnology innovation and diplomacy. Enhances competitive advantage in high-tech research sectors. Builds stronger alliances with other nations on scientific standards.
Creates frameworks for international research partnerships. Encourages knowledge-sharing with allied nations. Can accelerate discoveries through coordinated global efforts.
Biotechnology is a high-value industry with growth potential. Diplomatic leadership may attract investment and talent. Could create jobs in research and development sectors.
International biotech cooperation helps tackle diseases and health crises. Coordinated research can benefit public health worldwide. Establishes norms for responsible biotechnology development.
Bill lacks detailed summary of actual programs or budget. Vague language makes it hard to assess real costs and outcomes. Difficult to determine if diplomatic efforts will be effective.
Increased international collaboration may expose sensitive research. Biotech information could be misused by hostile nations. Requires careful protection of classified research.
New diplomatic initiatives require federal funding and staffing. Budget impact unknown without bill details. May divert resources from other priorities.
Coordinating biotechnology policy internationally is complex. Different countries have conflicting interests and standards. Success depends on sustained political commitment.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Other bills in this policy area
HR 10671
Securing Our Critical Infrastructure Act
HR 10695
United States Submarine Cable Security Policy Act of 2026
HR 7022
Mystic Alerts Act
S 5668
Methane Monitoring Science Act of 2026
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.